IDEAS home Printed from https://ideas.repec.org/e/pdo186.html
   My authors  Follow this author

Elizabeth Docteur

Personal Details

First Name:Elizabeth
Middle Name:
Last Name:Docteur
Suffix:
RePEc Short-ID:pdo186
[This author has chosen not to make the email address public]
http://www.linkedin.com/in/elizabethdocteur

Affiliation

(50%) Directorate for Employment, Labour and Social Affairs (ELS)
Organisation de Coopération et de Développement Économiques (OCDE)

Paris, France
http://www.oecd.org/els/
RePEc:edi:eloecfr (more details at EDIRC)

(50%) Organisation de Coopération et de Développement Économiques (OCDE)

Paris, France
http://www.oecd.org/
RePEc:edi:oecddfr (more details at EDIRC)

Research output

as
Jump to: Working papers

Working papers

  1. Elizabeth Docteur, 2009. "World Bank Health Sector Assists Crisis-Hit Eastern Europe Countries," World Bank Publications - Reports 10239, The World Bank Group.
  2. Elizabeth Docteur, 2009. "Mitigating the Impact of the Global Economic Crisis on Household Health Spending," World Bank Publications - Reports 10231, The World Bank Group.
  3. Zoltán Kaló & Elizabeth Docteur & Pierre Moïse, 2008. "Pharmaceutical Pricing and Reimbursement Policies in Slovakia," OECD Health Working Papers 31, OECD Publishing.
  4. Valérie Paris & Elizabeth Docteur, 2008. "Pharmaceutical Pricing and Reimbursement Policies in Germany," OECD Health Working Papers 39, OECD Publishing.
  5. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Sweden," OECD Health Working Papers 28, OECD Publishing.
  6. Valérie Paris & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Switzerland," OECD Health Working Papers 27, OECD Publishing.
  7. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Mexico," OECD Health Working Papers 25, OECD Publishing.
  8. Valérie Paris & Elizabeth Docteur, 2006. "Pharmaceutical Pricing and Reimbursement Policies in Canada," OECD Health Working Papers 24, OECD Publishing.
  9. Elizabeth Docteur & Howard Oxley, 2003. "Health-Care Systems: Lessons from the Reform Experience," OECD Health Working Papers 9, OECD Publishing.
  10. Elizabeth Docteur & Hannes Suppanz & Jaejoon Woo, 2003. "The US Health System: An Assessment and Prospective Directions for Reform," OECD Economics Department Working Papers 350, OECD Publishing.
  11. Lyle Nelson & Randall Brown & Marsha Gold & Anne Ciemnecki & Elizabeth Docteur, "undated". "Access to Care in Medicare HMOs, 1996," Mathematica Policy Research Reports f8852db522b543ceb44fa5d3a, Mathematica Policy Research.
  12. Marsha Gold & Lyle Nelson & Randall Brown & Anne Ciemnecki & Anna Aizer & Elizabeth Docteur, "undated". "Disabled Medicare Beneficiaries in HMOs," Mathematica Policy Research Reports 6c1439a75bff4df088e3efc13, Mathematica Policy Research.
  13. Eugene C. Rich & Elizabeth Docteur, "undated". "Politics and Policy of Comparative Effectiveness: Looking Back, Looking Ahead," Mathematica Policy Research Reports b0dc25a8e3cf424e89deb0de9, Mathematica Policy Research.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Elizabeth Docteur, 2009. "Mitigating the Impact of the Global Economic Crisis on Household Health Spending," World Bank Publications - Reports 10231, The World Bank Group.

    Cited by:

    1. Kyriopoulos, Ilias & Nikoloski, Zlatko & Mossialos, Elias, 2021. "Financial protection in health among the middle-aged and elderly: Evidence from the Greek economic recession," Health Policy, Elsevier, vol. 125(9), pages 1256-1266.

  2. Zoltán Kaló & Elizabeth Docteur & Pierre Moïse, 2008. "Pharmaceutical Pricing and Reimbursement Policies in Slovakia," OECD Health Working Papers 31, OECD Publishing.

    Cited by:

    1. Anna-Maria Fontrier & Jennifer Gill & Panos Kanavos, 2019. "International impact of external reference pricing: should national policy-makers care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1147-1164, November.
    2. Fontrier, Anna-Maria & Gill, Jennifer & Kanavos, Panos, 2019. "International impact of external reference pricing: should national policy makers care?," LSE Research Online Documents on Economics 100929, London School of Economics and Political Science, LSE Library.
    3. Kanavos, Panos, 2019. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," LSE Research Online Documents on Economics 101522, London School of Economics and Political Science, LSE Library.
    4. Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt, 2018. "The impact of physician-level drug budgets on prescribing behavior," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 213-222, March.
    5. Jennifer Gill & Anna-Maria Fontrier & Dionysis Kyriopoulos & Panos Kanavos, 2019. "Variations in external reference pricing implementation: does it matter for public policy?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(9), pages 1375-1397, December.
    6. Corinne Blanquart & Saskia Seidel & Ina Frenzel, 2018. "A conceptual framework to identify key drivers for logistics and transport demand - testing the scheme for goods movement in the pharmaceutical supply chain in France and Germany [Un cadre conceptu," Post-Print hal-01919122, HAL.
    7. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    8. Geng, Difei & Saggi, Kamal, 2020. "Optimal price regulations in international pharmaceutical markets with generic competition," Journal of Health Economics, Elsevier, vol. 71(C).
    9. Panos Kanavos & Anna-Maria Fontrier & Jennifer Gill & Olina Efthymiadou, 2020. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 129-151, February.

  3. Valérie Paris & Elizabeth Docteur, 2008. "Pharmaceutical Pricing and Reimbursement Policies in Germany," OECD Health Working Papers 39, OECD Publishing.

    Cited by:

    1. Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
    2. Gorecki, Paul K. & Nolan, Anne & Brick, Aoife & Lyons, Seán, 2012. "Pharmaceuticals Delivery in Ireland. Getting a Bigger Bang for the Buck," Research Series, Economic and Social Research Institute (ESRI), number RS24.
    3. Hossein, Zare & Gerard, Anderson, 2013. "Trends in cost sharing among selected high income countries—2000–2010," Health Policy, Elsevier, vol. 112(1), pages 35-44.
    4. Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt, 2018. "The impact of physician-level drug budgets on prescribing behavior," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 213-222, March.
    5. Corinne Blanquart & Saskia Seidel & Ina Frenzel, 2018. "A conceptual framework to identify key drivers for logistics and transport demand - testing the scheme for goods movement in the pharmaceutical supply chain in France and Germany [Un cadre conceptu," Post-Print hal-01919122, HAL.
    6. Mathias Kifmann & Sven Neelsen, 2010. "Germany's Struggle with Prices for Patent-protected Drugs," ifo DICE Report, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, vol. 8(03), pages 43-52, October.
    7. Geng, Difei & Saggi, Kamal, 2020. "Optimal price regulations in international pharmaceutical markets with generic competition," Journal of Health Economics, Elsevier, vol. 71(C).

  4. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Sweden," OECD Health Working Papers 28, OECD Publishing.

    Cited by:

    1. Thomas D. Szucs & Martina Weiss & Guido Klaus, 2017. "The enigma of value: in search of affordable and accessible health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 667-670, July.
    2. Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
    3. Charalabos-Markos Dintsios & Nadja Chernyak, 2022. "How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 287-290, May.
    4. Berger, Michael & Pock, Markus & Reiss, Miriam & Röhrling, Gerald & Czypionka, Thomas, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation," LSE Research Online Documents on Economics 116928, London School of Economics and Political Science, LSE Library.
    5. Adrian Levy & Craig Mitton & Karissa Johnston & Brian Harrigan & Andrew Briggs, 2010. "International Comparison of Comparative Effectiveness Research in Five Jurisdictions," PharmacoEconomics, Springer, vol. 28(10), pages 813-830, October.
    6. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    7. Melanie Levy, 2022. "The rise of the Swiss regulatory healthcare state: On preserving the just in the quest for the better (or less expensive?)," Regulation & Governance, John Wiley & Sons, vol. 16(2), pages 427-447, April.
    8. Greß, Stefan & Klaucke, Lena & Kötting, Cosima & May, Uwe & Wasem, Jürgen, 2008. "Preisregulierung von verschreibungspflichtigen Arzneimitteln in der gesetzlichen Krankenversicherung nach dem GKV-Wettbewerbsstärkungsgesetz," IBES Diskussionsbeiträge 170, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    9. Omer Ben-Aharon & Oren Shavit & Racheli Magnezi, 2017. "Does drug price-regulation affect healthcare expenditures?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 859-867, September.
    10. Annie Abello & Sharyn Lymer & Laurie Brown & Ann Harding & Ben Phillips, 2008. "Enhancing the Australian National Health Survey Data for Use in a Microsimulation Model of Pharmaceutical Drug Usage and Cost," Journal of Artificial Societies and Social Simulation, Journal of Artificial Societies and Social Simulation, vol. 11(3), pages 1-2.
    11. Pepijn Vemer & Maureen Rutten-van Mölken, 2011. "Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 397-404, October.
    12. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    13. Michael Berger & Markus Pock & Miriam Reiss & Gerald Röhrling & Thomas Czypionka, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms," International Journal of Health Economics and Management, Springer, vol. 23(1), pages 149-172, March.
    14. Nazila Yousefi & Mahyar Polroudi Moghaddam & Gita Afsharmanesh & Farzad Peiravian, 2020. "Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1503-1511, November.

  5. Valérie Paris & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Switzerland," OECD Health Working Papers 27, OECD Publishing.

    Cited by:

    1. Thomas D. Szucs & Martina Weiss & Guido Klaus, 2017. "The enigma of value: in search of affordable and accessible health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 667-670, July.
    2. Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
    3. Charalabos-Markos Dintsios & Nadja Chernyak, 2022. "How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 287-290, May.
    4. Kanavos, Panos, 2019. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," LSE Research Online Documents on Economics 101522, London School of Economics and Political Science, LSE Library.
    5. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    6. Melanie Levy, 2022. "The rise of the Swiss regulatory healthcare state: On preserving the just in the quest for the better (or less expensive?)," Regulation & Governance, John Wiley & Sons, vol. 16(2), pages 427-447, April.
    7. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    8. Nazila Yousefi & Mahyar Polroudi Moghaddam & Gita Afsharmanesh & Farzad Peiravian, 2020. "Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1503-1511, November.
    9. Panos Kanavos & Anna-Maria Fontrier & Jennifer Gill & Olina Efthymiadou, 2020. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 129-151, February.

  6. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Mexico," OECD Health Working Papers 25, OECD Publishing.

    Cited by:

    1. Thomas D. Szucs & Martina Weiss & Guido Klaus, 2017. "The enigma of value: in search of affordable and accessible health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 667-670, July.
    2. Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
    3. Reisinger, Markus & Saurí, Lluís & Zenger, Hans, 2019. "Parallel imports, price controls, and innovation," Journal of Health Economics, Elsevier, vol. 66(C), pages 163-179.
    4. Charalabos-Markos Dintsios & Nadja Chernyak, 2022. "How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 287-290, May.
    5. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    6. Melanie Levy, 2022. "The rise of the Swiss regulatory healthcare state: On preserving the just in the quest for the better (or less expensive?)," Regulation & Governance, John Wiley & Sons, vol. 16(2), pages 427-447, April.
    7. Jürgen Maurer, 2008. "Assessing horizontal equity in medication treatment among elderly Mexicans: which socioeconomic determinants matter most?," Health Economics, John Wiley & Sons, Ltd., vol. 17(10), pages 1153-1169, October.
    8. Jennifer M Manne & Callae S Snively & Janine M Ramsey & Marco Ocampo Salgado & Till Bärnighausen & Michael R Reich, 2013. "Barriers to Treatment Access for Chagas Disease in Mexico," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 7(10), pages 1-10, October.
    9. Jürgen Maurer, 2007. "Assessing Horizontal Equity in Medication Treatment Among Elderly Mexicans: Which Socioeconomic Determinants Matter Most?," MEA discussion paper series 07143, Munich Center for the Economics of Aging (MEA) at the Max Planck Institute for Social Law and Social Policy.
    10. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    11. Nazila Yousefi & Mahyar Polroudi Moghaddam & Gita Afsharmanesh & Farzad Peiravian, 2020. "Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1503-1511, November.

  7. Valérie Paris & Elizabeth Docteur, 2006. "Pharmaceutical Pricing and Reimbursement Policies in Canada," OECD Health Working Papers 24, OECD Publishing.

    Cited by:

    1. Don Husereau & Brian Feagan & Carl Selya-Hammer, 2018. "Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching," Applied Health Economics and Health Policy, Springer, vol. 16(3), pages 279-288, June.
    2. Adrian Levy & Craig Mitton & Karissa Johnston & Brian Harrigan & Andrew Briggs, 2010. "International Comparison of Comparative Effectiveness Research in Five Jurisdictions," PharmacoEconomics, Springer, vol. 28(10), pages 813-830, October.
    3. Andrew T. Ching & Robert Clark & Ignatius Horstmann & Hyunwoo Lim, 2016. "The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs," Marketing Science, INFORMS, vol. 35(1), pages 158-181, January.
    4. Anne Boring, 2010. "Political contributions to influence consumers: the example of the u.s. drug reimportation debate," Working Papers DT/2010/03, DIAL (Développement, Institutions et Mondialisation).
    5. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    6. Annie Abello & Sharyn Lymer & Laurie Brown & Ann Harding & Ben Phillips, 2008. "Enhancing the Australian National Health Survey Data for Use in a Microsimulation Model of Pharmaceutical Drug Usage and Cost," Journal of Artificial Societies and Social Simulation, Journal of Artificial Societies and Social Simulation, vol. 11(3), pages 1-2.
    7. Hui Zhang & Gregory Zaric, 2015. "Using price–volume agreements to manage pharmaceutical leakage and off-label promotion," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 747-761, September.
    8. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    9. Morgan, Steven G. & Thomson, Paige A. & Daw, Jamie R. & Friesen, Melissa K., 2013. "Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers," Health Policy, Elsevier, vol. 112(3), pages 248-254.
    10. Kirkpatrick, Colin & Raihan, Selim & Bleser, Adam & Prud'homme, Dan & Mayrand, Karel & Morin, Jean Frederic & Pollitt, Hector & Hinojosa, Leonith & Williams, Michael, 2011. "Trade sustainability impact assessment (SIA) on the comprehensive economic and trade agreement (CETA) between the EU and Canada: Final report," MPRA Paper 28812, University Library of Munich, Germany.
    11. Geng, Difei & Saggi, Kamal, 2020. "Optimal price regulations in international pharmaceutical markets with generic competition," Journal of Health Economics, Elsevier, vol. 71(C).

  8. Elizabeth Docteur & Howard Oxley, 2003. "Health-Care Systems: Lessons from the Reform Experience," OECD Health Working Papers 9, OECD Publishing.

    Cited by:

    1. Michele Moretto & Rosella Levaggi, 2004. "Investment in Hospital Care Technology under Different Purchasing Rules: A Real Option Approach," Working Papers 2004.75, Fondazione Eni Enrico Mattei.
    2. Hans Fehr & Sabine Jokisch & Laurence J. Kotlikoff, 2005. "Will China Eat Our Lunch or Take us to Dinner? - Simulating the Transition Paths of the U.S., Eu, Japan and China," Boston University - Department of Economics - The Institute for Economic Development Working Papers Series dp-151, Boston University - Department of Economics.
    3. Rudoler, David & Laporte, Audrey & Barnsley, Janet & Glazier, Richard H. & Deber, Raisa B., 2015. "Paying for primary care: A cross-sectional analysis of cost and morbidity distributions across primary care payment models in Ontario Canada," Social Science & Medicine, Elsevier, vol. 124(C), pages 18-28.
    4. Koornneef, Erik J. & Robben, Paul B.M. & Al Seiari, Mohammed B. & Al Siksek, Zaid, 2012. "Health system reform in the Emirate of Abu Dhabi, United Arab Emirates," Health Policy, Elsevier, vol. 108(2), pages 115-121.
    5. Adam Wagstaff, 2010. "Social health insurance reexamined," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 503-517, May.
    6. Shao-Wei Yang & Kuo-Chung Chu & Victor B. Kreng, 2021. "The Impact of Global Budgeting on the Efficiency of Healthcare under a Single-Payer System in Taiwan," IJERPH, MDPI, vol. 18(20), pages 1-14, October.
    7. Guillem López & David McDaid & Joan Costa-Font, 2006. "Health care management autonomy: Evidence from the Catalonian hospital sector in a decentralised Spain," Working Papers, Research Center on Health and Economics 993, Department of Economics and Business, Universitat Pompeu Fabra.
    8. Katharina Hauck & Xiaohui Zhang, 2016. "Heterogeneity in the Effect of Common Shocks on Healthcare Expenditure Growth," Health Economics, John Wiley & Sons, Ltd., vol. 25(9), pages 1090-1103, September.
    9. Nikolaos Grigorakis & Christos Floros & Haritini Tsangari & Evangelos Tsoukatos, 2017. "Combined social and private health insurance versus catastrophic out of pocket payments for private hospital care in Greece," International Journal of Health Economics and Management, Springer, vol. 17(3), pages 261-287, September.
    10. Joshua Cohen, 2006. "Transatlantic Convergence with Respect to the Fourth Hurdle?," PharmacoEconomics, Springer, vol. 24(2), pages 87-94, December.
    11. Karen Eggleston & Li Ling & Meng Qingyue & Magnus Lindelow & Adam Wagstaff, 2008. "Health service delivery in China: a literature review," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 149-165, February.
    12. Thiess Büttner & Peter Egger & Herbert Hofmann & Christian Holzner & Mario Larch & Volker Meier & Chang Woon Nam & Rigmar Osterkamp & Rüdiger Parsche & Martin Werding, 2006. "Tu felix Austria: Wachstums- und Beschäftigungspolitik in Österreich und Deutschland im Vergleich," ifo Forschungsberichte, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, number 31, September.
    13. Sabine Jokisch & Laurence J. Kotlikoff, 2005. "Simulating the Dynamic Macroeconomic and Microeconomic Effects of the FairTax," NBER Working Papers 11858, National Bureau of Economic Research, Inc.
    14. Sean Dougherty & Luca Lorenzoni & Alberto Marino & Fabrice Murtin, 2019. "The impact of decentralisation on the performance of health care systems: A non-linear relationship," OECD Working Papers on Fiscal Federalism 27, OECD Publishing.
    15. Samuel S. Lieberman & Adam Wagstaff, 2009. "Health Financing and Delivery in Vietnam : Looking Forward," World Bank Publications - Books, The World Bank Group, number 2594.
    16. Alison Booth & Nick Carroll, 2005. "The Health Status of Indigenous and Non-Indigenous Australians," CEPR Discussion Papers 486, Centre for Economic Policy Research, Research School of Economics, Australian National University.
    17. Alena Kimakova, 2010. "A Political Economy Model of Health Insurance Policy," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 38(1), pages 23-36, March.
    18. Cacace, Mirella, 2007. "The changing public/private mix in the American Health Care System," TranState Working Papers 58, University of Bremen, Collaborative Research Center 597: Transformations of the State.
    19. Majo, M.C., 2010. "A microeconometric analysis of health care utilization in Europe," Other publications TiSEM 1cf5fd2f-8146-4ef8-8eb5-e, Tilburg University, School of Economics and Management.
    20. Peter Carroll & Aynsley Kellow, 2011. "The OECD," Books, Edward Elgar Publishing, number 4266.
    21. Jochen Hartwig & Jan-Egbert Sturm, 2017. "Testing the Grossman model of medical spending determinants with macroeconomic panel data," KOF Working papers 17-426, KOF Swiss Economic Institute, ETH Zurich.
    22. Jochen Hartwig & Jan-Egbert Sturm, 2012. "An outlier-robust extreme bounds analysis of the determinants of health-care expenditure growth," KOF Working papers 12-307, KOF Swiss Economic Institute, ETH Zurich.
    23. Hertog, Friso den & Groen, Marjan & Weehuizen, Rifka, 2005. "Mapping Health Care Innovation: Tracing Walls & Ceilings," Research Memorandum 013, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).
    24. Pammolli, Fabio & Riccaboni, Massimo & Oglialoro, Claudia & Magazzini, Laura & Baio, Gianluca & Salerno, Nicola, 2005. "Medical Devices Competitiveness and Impact on Public Health Expenditure," MPRA Paper 16021, University Library of Munich, Germany.
    25. Blazej Lyszczarz, 2016. "The effect of health care model on health systems' responses to economic crises," Ekonomia i Prawo, Uniwersytet Mikolaja Kopernika, vol. 15(4), pages 493-501, December.
    26. Nozaki, Masahiro & Kashiwase, Kenichiro & Saito, Ikuo, 2017. "Health spending in Japan: Macro-fiscal implications and reform options," The Journal of the Economics of Ageing, Elsevier, vol. 9(C), pages 156-171.
    27. Booth, Alison L. & Carroll, Nick, 2008. "Economic status and the Indigenous/non-Indigenous health gap," Economics Letters, Elsevier, vol. 99(3), pages 604-606, June.
    28. Jacek Klich, 2008. "Globalizacja usług zdrowotnych," Gospodarka Narodowa. The Polish Journal of Economics, Warsaw School of Economics, issue 4, pages 21-40.
    29. Kumpmann, Ingmar, 2009. "Monopolistic Competition and Costs in the Health Care Sector," IWH Discussion Papers 17/2009, Halle Institute for Economic Research (IWH).
    30. Pablo Gottret & George Schieber, 2006. "Health Financing Revisited : A Practitioner's Guide," World Bank Publications - Books, The World Bank Group, number 7094.
    31. Majo, Maria Cristina & van Soest, Arthur, 2012. "Income and health care utilization among the 50+ in Europe and the US," Applied Econometrics, Russian Presidential Academy of National Economy and Public Administration (RANEPA), vol. 28(4), pages 3-22.
    32. Hossein, Zare & Gerard, Anderson, 2013. "Trends in cost sharing among selected high income countries—2000–2010," Health Policy, Elsevier, vol. 112(1), pages 35-44.
    33. Mikkers, Misja, 2016. "The Dutch Healthcare System in International Perspective," Other publications TiSEM 800704a0-24ee-4830-8659-2, Tilburg University, School of Economics and Management.
    34. Iga Rudawska, 2011. "Integrated health care delivery - on the road to improved effectiveness (Zintegrowana opieka zdrowotna - w poszukiwaniu poprawy efektywnosci)," Problemy Zarzadzania, University of Warsaw, Faculty of Management, vol. 9(33), pages 140-152.
    35. Wren, Maev-Ann & Connolly, Sheelagh & Cunningham, Nathan, 2015. "An Examination of the Potential Costs of Universal Health Insurance in Ireland," Research Series, Economic and Social Research Institute (ESRI), number RS45.
    36. Julien Mousquès & Yann Bourgueil & Philippe Le Fur & Engin Yilmaz, 2010. "Effect of a French Experiment of Team Work between General Practitioners and Nurses on Efficacy and Cost of Type 2 Diabetes Patients Care," Working Papers DT29, IRDES institut for research and information in health economics, revised Jan 2010.
    37. Christine André & Philippe Batifoulier & Mariana Jansen-Ferreira, 2016. "Privatisation de la santé en Europe. Un outil de classification des réformes," Working Papers hal-01256505, HAL.
    38. Luigi Siciliani & Rossella Verzulli, 2009. "Waiting times and socioeconomic status among elderly Europeans: evidence from SHARE," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1295-1306, November.
    39. Pammolli, Fabio & Riccaboni, Massimo & Magazzini, Laura, 2008. "The Sustainability of European Health Care Systems: Beyond Income and Ageing," MPRA Paper 16026, University Library of Munich, Germany.
    40. Pelletier-Fleury, Nathalie & Le Vaillant, Marc & Hebbrecht, Gilles & Boisnault, Philippe, 2007. "Determinants of preventive services in general practice: A multilevel approach in cardiovascular domain and vaccination in France," Health Policy, Elsevier, vol. 81(2-3), pages 218-227, May.
    41. Anni Ankjær-Jensen & Pernille Rosling & Lone Bilde, 2006. "Variable prospective financing in the Danish hospital sector and the development of a Danish case-mix system," Health Care Management Science, Springer, vol. 9(3), pages 259-268, August.
    42. Betliy Oleksandra & Kuziakiv Oksana & Onishchenko Katerina, 2007. "The evaluation of health care system in Ukraine in the context of structural and quality-enhancing reforms," EERC Working Paper Series 07/07e, EERC Research Network, Russia and CIS.
    43. Daniel Bennett & Che-Lun Hung & Tsai-Ling Lauderdale, 2015. "Health Care Competition and Antibiotic Use in Taiwan," Journal of Industrial Economics, Wiley Blackwell, vol. 63(2), pages 371-393, June.
    44. Sarah M. Hofmann & Andrea M. Muehlenweg, 2016. "Gatekeeping in German Primary Health Care - Impacts on Coordination of Care, Quality Indicators and Ambulatory Costs," CINCH Working Paper Series 1605, Universitaet Duisburg-Essen, Competent in Competition and Health, revised Sep 2016.
    45. Victoria Fan and William Savedoff, 2014. "The Health Financing Transition: A Conceptual Framework and Empirical Evidence - Working Paper 358," Working Papers 358, Center for Global Development.
    46. Böhm, Katharina & Schmid, Achim & Götze, Ralf & Landwehr, Claudia & Rothgang, Heinz, 2012. "Classifying OECD healthcare systems: A deductive approach," TranState Working Papers 165, University of Bremen, Collaborative Research Center 597: Transformations of the State.
    47. André, Christine, 2015. "Les systèmes de santé européens en longue période," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, vol. 17.
    48. Thomas DiPrete & Ellen Verbakel, 2007. "The Value of Non-Working Time Incorporated in Quality of Life Comparisons: The Case of the U.S. vs. the Netherlands," LIS Working papers 464, LIS Cross-National Data Center in Luxembourg.
    49. Fan, Victoria Y. & Savedoff, William D., 2014. "The health financing transition: A conceptual framework and empirical evidence," Social Science & Medicine, Elsevier, vol. 105(C), pages 112-121.
    50. Claudia Boghicevici, 2023. "The Analysis of Health Infrastructure in the Public Health System in Romania," Manager Journal, Faculty of Business and Administration, University of Bucharest, vol. 37(1), pages 52-66, May.
    51. Barros, Pedro Pita & Martinez-Giralt, Xavier, 2008. "Selecting health care providers: "Any willing provider" vs. negotiation," European Journal of Political Economy, Elsevier, vol. 24(2), pages 402-414, June.
    52. Daniele Fabbri & Chiara Monfardini, 2006. "Rationing The Public Provision Of Healthcare In The Presence Of Private Supplements: Evidence From The Italian Nhs," CHILD Working Papers wp21_06, CHILD - Centre for Household, Income, Labour and Demographic economics - ITALY.
    53. Alexandra A. Sidorenko & James R.G. Butler, 2007. "Financing Health Insurance in Asia Pacific Countries," Asian-Pacific Economic Literature, The Crawford School, The Australian National University, vol. 21(1), pages 34-54, May.
    54. Paul Scuffham & Jennifer Whitty & Matthew Taylor & Ruth Saxby, 2010. "Health system choice," Applied Health Economics and Health Policy, Springer, vol. 8(2), pages 89-97, March.
    55. World Bank, 2008. "Serbia : Decentralization and Local Service Delivery," World Bank Publications - Reports 8099, The World Bank Group.
    56. Atella, Vincenzo & Brunetti, Marianna & Maestas, Nicole, 2012. "Household portfolio choices, health status and health care systems: A cross-country analysis based on SHARE," Journal of Banking & Finance, Elsevier, vol. 36(5), pages 1320-1335.
    57. Owen Smith & Son Nam Nguyen, 2013. "Getting Better : Improving Health System Outcomes in Europe and Central Asia," World Bank Publications - Books, The World Bank Group, number 13832.
    58. Böhm, Katharina & Schmid, Achim & Götze, Ralf & Landwehr, Claudia & Rothgang, Heinz, 2013. "Five types of OECD healthcare systems: Empirical results of a deductive classification," Health Policy, Elsevier, vol. 113(3), pages 258-269.
    59. Davide Consoli & Andrea Mina, 2009. "An evolutionary perspective on health innovation systems," Journal of Evolutionary Economics, Springer, vol. 19(2), pages 297-319, April.
    60. Mr. Masahiro Nozaki & Kenichiro Kashiwase & Ikuo Saito, 2014. "Health Spending in Japan: Macro-Fiscal Implications and Reform Options," IMF Working Papers 2014/142, International Monetary Fund.
    61. World Bank, 2008. "Kosovo : Health Financing Reform Study," World Bank Publications - Reports 8121, The World Bank Group.
    62. António Afonso & Sónia Fernandes, 2008. "Assessing Hospital Efficiency: Non-parametric Evidence for Portugal," Working Papers Department of Economics 2008/07, ISEG - Lisbon School of Economics and Management, Department of Economics, Universidade de Lisboa.
    63. Jochen Hartwig & Jan-Egbert Sturm, 2014. "Robust determinants of health care expenditure growth," Applied Economics, Taylor & Francis Journals, vol. 46(36), pages 4455-4474, December.
    64. Hans Fehr & Sabine Jokisch & Laurence J. Kotlikoff, 2005. "Will China Eat Our Lunch or Take Us Out to Dinner? Simulating the Transition Paths of the U.S., EU, Japan, and China," NBER Working Papers 11668, National Bureau of Economic Research, Inc.
    65. Panos Kanavos & Olivier Wouters & Aris Angelis & David Tordrup & Panos Kanavos, 2017. "Is the Funding of Public National Health Systems Sustainable over the Long Term? Evidence from Eight OECD Countries," Global Policy, London School of Economics and Political Science, vol. 8, pages 7-22, March.
    66. Thomas P. Weil, 2016. "What can the Canadians and Americans learn from each other's health care systems?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(3), pages 349-370, July.
    67. Philippe Ulmann, 2004. "Est-il possible (souhaitable) de maîtriser les dépenses de santé ?," Revue d'Économie Financière, Programme National Persée, vol. 76(3), pages 19-37.
    68. Polyzos, Nikolaos & Karanikas, Haralampos & Thireos, Eleftherios & Kastanioti, Catherine & Kontodimopoulos, Nick, 2013. "Reforming reimbursement of public hospitals in Greece during the economic crisis: Implementation of a DRG system," Health Policy, Elsevier, vol. 109(1), pages 14-22.

  9. Elizabeth Docteur & Hannes Suppanz & Jaejoon Woo, 2003. "The US Health System: An Assessment and Prospective Directions for Reform," OECD Economics Department Working Papers 350, OECD Publishing.

    Cited by:

    1. Cacace, Mirella, 2007. "The changing public/private mix in the American Health Care System," TranState Working Papers 58, University of Bremen, Collaborative Research Center 597: Transformations of the State.
    2. Kumpmann, Ingmar, 2009. "Monopolistic Competition and Costs in the Health Care Sector," IWH Discussion Papers 17/2009, Halle Institute for Economic Research (IWH).
    3. Stolpe, Michael, 2003. "Ressourcen und Ergebnisse der globalen Gesundheitsökonomie: Einführung und Überblick," Kiel Working Papers 1177, Kiel Institute for the World Economy (IfW Kiel).
    4. Goodman, Steffie, 2007. "Piercing the veil: The marginalization of midwives in the United States," Social Science & Medicine, Elsevier, vol. 65(3), pages 610-621, August.
    5. Jan Mertl, 2014. "The Impact of Longevity on Health Care Systems," European Research Studies Journal, European Research Studies Journal, vol. 0(1), pages 85-100.
    6. Greß, Stefan & Walendzik, Anke & Wasem, Jürgen, 2005. "Nichtversicherte Personen im Krankenversicherungssystem der Bundesrepublik Deutschland: Bestandsaufnahme und Lösungsmöglichkeiten," IBES Diskussionsbeiträge 147, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).

  10. Lyle Nelson & Randall Brown & Marsha Gold & Anne Ciemnecki & Elizabeth Docteur, "undated". "Access to Care in Medicare HMOs, 1996," Mathematica Policy Research Reports f8852db522b543ceb44fa5d3a, Mathematica Policy Research.

    Cited by:

    1. van de Ven, Wynand P. M. M. & Beck, Konstantin & Buchner, Florian & Chernichovsky, Dov & Gardiol, Lucien & Holly, Alberto & Lamers, Leida M. & Schokkaert, Erik & Shmueli, Amir & Spycher, Stephan & Van, 2003. "Risk adjustment and risk selection on the sickness fund insurance market in five European countries," Health Policy, Elsevier, vol. 65(1), pages 75-98, July.
    2. Marsha Gold & Lori Achman, "undated". "Trends in Premiums, Cost-Sharing, and Benefits in Medicare+Choice Health Plans, 1999-2001," Mathematica Policy Research Reports 9b7d9ff2f0b24ee49dfc99f1c, Mathematica Policy Research.

  11. Marsha Gold & Lyle Nelson & Randall Brown & Anne Ciemnecki & Anna Aizer & Elizabeth Docteur, "undated". "Disabled Medicare Beneficiaries in HMOs," Mathematica Policy Research Reports 6c1439a75bff4df088e3efc13, Mathematica Policy Research.

    Cited by:

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 8 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (6) 2003-03-10 2007-01-23 2007-08-08 2007-08-08 2008-03-08 2009-01-17. Author is listed
  2. NEP-REG: Regulation (2) 2007-01-23 2007-08-08
  3. NEP-COM: Industrial Competition (1) 2007-02-17
  4. NEP-LAB: Labour Economics (1) 2003-12-14

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Elizabeth Docteur should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.